SCHEMBL19078396

SCHEMBL19078396

C=Cc1ccc(C(F)(F)F)cc1N1CCC(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ NOTUM Q6P988 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.40
▸ FFAR2 O15552 1/20 0.39
▸ STS P08842 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ FFAR4 Q5NUL3 2/20 0.38
▸ SERPINE1 P05121 1/20 0.38
▸ ENPP2 Q13822 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17305174 0.90 LMNA (0.44) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19078423 0.89 MAPT (0.43) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19078390 0.88 MAPT (0.42) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19078487 0.86 NOTUM (0.42) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19088117 0.86 NOTUM (0.42) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19078474 0.86 ENPP2 (0.42) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19088119 0.85 NOTUM (0.41) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19078405 0.84 FFAR4 (0.39) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL17305317 0.84 ENPP2 (0.44) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19088116 0.84 ENPP2 (0.44) MAPTCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981960-B2 Pyrrolidine compound and application as melanocortin receptor agonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-05-29 — — US disclosed
US-20170190697-A1 NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190697-A1 NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST MC1R, MC5R, MC3R MAPT 3317/4885CYP1A2 1825/4885CYP3A4 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback